Drugs / Orphenadrine
Orphenadrine
also known as
Disipal · Invagesic · Mefenamine · Mephenamin · Mialgin · Norflex · Norgesic · NSC-757238 · +14 more
Small molecule targets HRH1, SLC6A2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | DISIPAL | — | 1957-05-10 | fda.gov ↗ |
Trials 10
1956195719581959196019611962196319641965196619671968196919701971197219731974197519761977197819791980198119821983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028202920302031
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02485145 | Jul → Dec 2015 | osteoarthritis, hand | Transdermal Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02985671 | Jan → Sep 2021 | — | Ache Laboratorios Farmaceuticos S.A. | Unknown | No outcome recorded |
| Phase 3 | NCT02423395 | Jan 2015 → Dec 2028 expected | cirrhosis of liver | Tanta University | Recruiting | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT05413902 | Apr 2021 → Jan 2022 | — | University of Puerto Rico | Completed | No outcome recorded |
| Phase 4 | NCT04835116 | Apr → Oct 2019 | — | Armed Forces Institute of Urology, Rawalpindi | Completed | No outcome recorded |
| Phase 4 | NCT03493490 | Mar 2018 → May 2019 | neuropathy, painful | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT02958566 | Jan → Dec 2017 | colon carcinoma, constipation disorder, diverticulitis of colon, paralytic ileus +1 | University of Illinois College of Medicine at Peoria | Unknown | No outcome recorded |
| Phase 4 | NCT02449369 | Apr 2015 → Sep 2016 | — | AdventHealth | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05322603 | Mar → Aug 2022 | — | Petrovsky National Research Centre of Surgery | Completed | No outcome recorded |
| — | NCT04509336 | Aug → Dec 2020 | cirrhosis of liver | Mansoura University | Terminated | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 4 | NCT07109882 Comparator | Jul → Aug 2025 overdue | bruxism | University of Baghdad | Recruiting | No outcome recorded |
| Phase 4 | NCT02665286 Comparator | Mar 2016 → Apr 2017 | — | Montefiore Medical Center | Completed | No outcome recorded |
| — | NCT01263652 Comparator | Dec 2010 → Jun 2019 | — | Western Galilee Hospital-Nahariya | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 29 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | orphenadrine | “Neodolpasse® Infusion Solution combines 75 mg (250 mL) of the NSAID diclofenac with 30 mg of the muscle-relaxant orphenadrine.” NCT03493490 ↗12“Efficiency and Safety a Fixed Combination of Orphenadrine and Diclofenac for Postoperative Analgesia” NCT05322603 ↗ “Orphenadrine 5% - an anticholinergic drug of the ethanolamine antihistamine class.” NCT02485145 ↗ |
| Known as | Disipal | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Invagesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Mefenamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Mephenamin | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Mialgin | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Norflex | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Norgesic | “the second group will receive Norgesic (orphenadrine Citrate) twice daily for two weeks as well.” NCT07109882 ↗ |
| Known as | NSC-757238 | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | NSC-82357 | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orfenadrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrin | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine (chloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine Citrate | “This group will receive Orphenadrine Citrate twice daily for two weeks.” NCT07109882 ↗ |
| Known as | Orphenadrine citrate component of invagesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine citrate component of invagesic forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine citrate component of norgesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine citrate component of orphengesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine citrate component of orphengesic forte | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine dihydrogen citrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphenadrine hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | ORPHENADRINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Known as | Orphengesic | ChEMBL registry synonym — accepted as the source's own label CHEMBL900 ↗ |
| Action | Inhibit | “Orphenadrine 5% - an anticholinergic drug of the ethanolamine antihistamine class.” NCT02485145 ↗ |
| Modality | Small molecule | — CHEMBL900 ↗ |
| Route | Intramuscular | “IM/PO” NCT01263652 ↗ |
| Route | Oral | “IM/PO” NCT01263652 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL900 ↗ |
| Target | SLC6A2 | “Norepinephrine transporter inhibitor” CHEMBL900 ↗ |